BeOne Medicines (ONC) Income towards Parent Company (2015 - 2026)
BeOne Medicines (ONC) reported Income towards Parent Company of $227.4 million for Q1 2026, up 17802.13% year-over-year from N/an in Q1 2025, and up 241.88% on a QoQ basis from $66.5 million in Q4 2025.
BeOne Medicines (ONC) has 12 years of Income towards Parent Company data on file, last reported at $227.4 million in Q1 2026.
- Quarterly Income towards Parent Company rose 17802.13% year-over-year to $227.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $513.0 million (up 230.75% YoY) and the FY2025 annual result came in at $286.9 million, up 144.5% from the prior year.
- Income towards Parent Company grew to $227.4 million in Q1 2026 per ONC's latest filing, from $66.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $227.4 million in Q1 2026 and bottomed at -$565.7 million in Q2 2022.
- The 5-year median for Income towards Parent Company is -$151.9 million (2024), against an average of -$177.4 million.
- The widest annual swing landed in 2022, when Income towards Parent Company slumped 754.48%; it then soared 17802.13% in 2026.
- Tracing ONC's Income towards Parent Company over 5 years: stood at -$445.3 million in 2022, then rose by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 143.79% to $66.5 million in 2025, then soared by 241.88% to $227.4 million in 2026.
- Per Business Quant, the three latest ONC Income towards Parent Company figures stand at $227.4 million (Q1 2026), $66.5 million (Q4 2025), and $124.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.36 Mn |
| Dec 31, 2025 | 66.50 Mn |
| Sep 30, 2025 | 124.84 Mn |
| Jun 30, 2025 | 94.32 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | -151.88 Mn |
| Sep 30, 2024 | -121.35 Mn |
| Jun 30, 2024 | -120.41 Mn |
| Mar 31, 2024 | -251.15 Mn |
| Dec 31, 2023 | -367.55 Mn |
| Sep 30, 2023 | 215.41 Mn |
| Jun 30, 2023 | -381.14 Mn |
| Mar 31, 2023 | -348.43 Mn |
| Dec 31, 2022 | -445.34 Mn |
| Sep 30, 2022 | -557.56 Mn |
| Jun 30, 2022 | -565.73 Mn |
| Mar 31, 2022 | -435.20 Mn |
| Dec 31, 2021 | -590.68 Mn |
| Sep 30, 2021 | -438.11 Mn |
| Jun 30, 2021 | -480.34 Mn |
| Mar 31, 2021 | 66.50 Mn |
| Dec 31, 2020 | -500.72 Mn |
| Sep 30, 2020 | -435.73 Mn |
| Jun 30, 2020 | -346.51 Mn |
| Mar 31, 2020 | -379.78 Mn |
| Dec 31, 2019 | -404.05 Mn |
| Sep 30, 2019 | -324.42 Mn |
| Jun 30, 2019 | -103.34 Mn |
| Mar 31, 2019 | -181.98 Mn |
| Dec 31, 2018 | -281.16 Mn |
| Sep 30, 2018 | -157.48 Mn |
| Jun 30, 2018 | -157.72 Mn |
| Mar 31, 2018 | -105.12 Mn |
| Dec 31, 2017 | -113.70 Mn |
| Sep 30, 2017 | 117.28 Mn |
| Jun 30, 2017 | -60.68 Mn |
| Mar 31, 2017 | -50.62 Mn |
| Dec 31, 2016 | -37.60 Mn |
| Sep 30, 2016 | -35.49 Mn |
| Jun 30, 2016 | -24.12 Mn |
| Mar 31, 2016 | -22.00 Mn |
| Dec 31, 2015 | 24.60 Mn |
| Sep 30, 2015 | -14.00 Mn |
| Jun 30, 2015 | -5.64 Mn |
| Mar 31, 2015 | -10.21 Mn |